Assessment of Alterations in Immune Function During Pregnancy and Post Parturition
NCT ID: NCT01200979
Last Updated: 2019-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
41 participants
OBSERVATIONAL
2011-09-30
2019-10-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes
NCT04659759
Primitive Immunodeficiency and Pregnancy
NCT04581460
Evaluation of Humoral Immunity Following COVID-19 in Pregnancy
NCT04568044
Maternal Immunization: Giving Immunity For Tomorrow
NCT01496079
Multisite Observational Maternal and Infant Study for COVID-19
NCT05031468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We also plan to evaluate serum cytokine panels, PBMC by flow cytometry, and PBMC for microarray of gene expression, before and after administration of the influenza vaccine in up to 20 of the 40 pregnant subjects. Antibody levels will be measured as well.
A comparison of any observed changes will be made with those previously reported for in vitro and in vivo studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pregnant flu vaccinated
pregnant women that choose to receive the seasonal flu vaccine
No interventions assigned to this group
pregnant non-flu vaccinated
pregnant women that do not receive the flu vaccine
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be between the ages of 18-45 years old.
* Have a positive pregnancy test (urine).
* Be of an estimated gestational age of between 10 and 20 weeks either by ultrasound or LMP.
* Have an identified primary care provider for the pregnancy.
* Be willing to sign the collaborative study consent form from CHI.
* Be willing to have samples collected and stored for future research and immunological studies
* Be willing to sign the collaborative study consent form for normal volunteers from CHI
Up to twenty pregnant subjects who agree to receive the seasonal influenza vaccine must:
* Have no history of allergic reaction to the vaccine or its contents
* Not have received the vaccine from other providers this flu season
* Agree to have an additional 20cc of blood drawn at both Day +1 and Day +7 post-vaccine for immune analysis.
EXCLUSION CRITIERIA:
A subject will be excluded if she:
* Has an identified underlying chronic medical condition that may adversely affect the immune system (e.g., autoimmune, HIV, or hematologic) or the need for immunomodulating medications (e.g., oral steroids) within 30 days prior to conception for a suspected immune disorder. Oral steroid use for any other reason must have been discontinued for at least 30 days prior to participation.
* Is found to have a Hemoglobin reading of less than 8g/dL.
* Has any other medical condition which, in the opinion of the Principal Investigator, poses an unacceptable risk to the subject s participation in the study.
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christa S Zerbe, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pejcic-Karapetrovic B, Gurnani K, Russell MS, Finlay BB, Sad S, Krishnan L. Pregnancy impairs the innate immune resistance to Salmonella typhimurium leading to rapid fatal infection. J Immunol. 2007 Nov 1;179(9):6088-96. doi: 10.4049/jimmunol.179.9.6088.
Luppi P. How immune mechanisms are affected by pregnancy. Vaccine. 2003 Jul 28;21(24):3352-7. doi: 10.1016/s0264-410x(03)00331-1.
Zhao J, Lei Z, Liu Y, Li B, Zhang L, Fang H, Song C, Wang X, Zhang GM, Feng ZH, Huang B. Human pregnancy up-regulates Tim-3 in innate immune cells for systemic immunity. J Immunol. 2009 May 15;182(10):6618-24. doi: 10.4049/jimmunol.0803876.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-I-0205
Identifier Type: -
Identifier Source: secondary_id
100205
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.